Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LFST
stocks logo

LFST

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
378.05M
+16.14%
-0.008
-58%
381.48M
+14.57%
-0.000
-98.5%
Estimates Revision
The market is revising Upward the revenue expectations for LifeStance Health Group, Inc. (LFST) for FY2025, with the revenue forecasts being adjusted by 0.37% over the past three months. During the same period, the stock price has changed by 20.30%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.37%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-44.32%
In Past 3 Month
Stock Price
Go Up
up Image
+20.30%
In Past 3 Month
Wall Street analysts forecast LFST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFST is 9.00 USD with a low forecast of 8.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast LFST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFST is 9.00 USD with a low forecast of 8.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.460
sliders
Low
8.00
Averages
9.00
High
10.00
Current: 6.460
sliders
Low
8.00
Averages
9.00
High
10.00
BMO Capital
Outperform
initiated
$8
2025-11-12
Reason
BMO Capital
Price Target
$8
2025-11-12
initiated
Outperform
Reason
BMO Capital initiated coverage of LifeStance with an Outperform rating and $8 price target. With new initiatives in place to boost growth, attention has turned to their effectiveness, the analyst tells investors in a research note. LifeStance's focus is shifting from solely adding clinicians to also enhancing their productivity, while expanding into specialty care offers additional upside, the firm says, adding that the stock appears attractively valued.
UBS
Buy
maintain
$9 -> $10
2025-11-07
Reason
UBS
Price Target
$9 -> $10
2025-11-07
maintain
Buy
Reason
UBS raised the firm's price target on LifeStance to $10 from $9 and keeps a Buy rating on the shares. LifeStance posted a solid beat across the board for Q3 and raised its fiscal 2025 profit outlook, the analyst tells investors in a research note.
UBS
Buy
maintain
$9
2025-08-08
Reason
UBS
Price Target
$9
2025-08-08
maintain
Buy
Reason
UBS raised the firm's price target on LifeStance to $9 from $8.50 and keeps a Buy rating on the shares.
BTIG
Buy
initiated
$8
2025-07-25
Reason
BTIG
Price Target
$8
2025-07-25
initiated
Buy
Reason
BTIG initiated coverage of LifeStance with a Buy rating and $8 price target. The firm says LifeStance is one of the country's largest outpatient mental health providers. It notes that 90% of the company's patients are commercially insured, making it well networked into health systems and referring hospitals. BTIG believes commercially insured lives are the most attractive segment of the market since insurance rates are typically well above Medicare and Medicaid rates. LifeStance is differentiated given its in-person and virtual care model, the analyst tells investors in a research note.
UBS
Kevin Caliendo
Neutral -> Buy
upgrade
$8.50
2025-05-27
Reason
UBS
Kevin Caliendo
Price Target
$8.50
2025-05-27
upgrade
Neutral -> Buy
Reason
Keybanc
Steve Dechert
Buy
Initiates
$9
2025-04-08
Reason
Keybanc
Steve Dechert
Price Target
$9
2025-04-08
Initiates
Buy
Reason
KeyBanc initiated coverage of LifeStance with an Overweight rating and $9 price target. The firm expects mid-teens organic sales growth over the next couple of years from the company, driven mainly by higher visit volumes on further clinician adds and increasing total revenue per visit on payor reimbursement rate improvement. It also expects margin expansion on the company's recently optimized real estate footprint, clinician productivity, higher margin specialty offerings, and continued cost efficiencies driven by technology enhancements.
See All Ratings

Valuation Metrics

The current forward P/E ratio for LifeStance Health Group Inc (LFST.O) is 221.99, compared to its 5-year average forward P/E of -6.96. For a more detailed relative valuation and DCF analysis to assess LifeStance Health Group Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.96
Current PE
221.99
Overvalued PE
86.68
Undervalued PE
-100.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
45.10
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
78.54
Undervalued EV/EBITDA
11.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.95
Current PS
0.00
Overvalued PS
5.20
Undervalued PS
0.70
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

LFST News & Events

Events Timeline

(ET)
2025-11-06
06:13:45
LifeStance Supports FY25 Revenue Forecast of $1.41B-$1.43B, Aligning with Consensus of $1.41B
select
2025-11-06
06:12:59
LifeStance Announces Q3 Revenue of $363.8 Million, Exceeding Consensus Estimate of $355.03 Million
select
2025-10-28 (ET)
2025-10-28
09:04:47
LifeStance Collaborates with Calm Health to Offer Tailored Mental Health Services
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-13Benzinga
BMO Capital Begins Coverage of LifeStance Health Group with Outperform Rating and Sets Price Target at $8

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform provides essential tools and information that traders use daily to succeed in the markets.

[object Object]
Preview
2.0
11-05Newsfilter
Almost 70% of Americans Experience Pressure to Seem Happier Than They Actually Are This Holiday Season

  • Survey Findings: A LifeStance Health survey reveals that 57% of Americans find the holiday season stressful, with Millennials and Gen Z feeling the most pressure to attend gatherings and appear happy.

  • Generational Trends: 64% of respondents would prefer to skip some holiday gatherings, with 34% of Millennials and 33% of Gen Z wanting to avoid most or all events.

  • Feelings of Loneliness: 51% of respondents report feeling lonely during the holidays, even in the company of loved ones, while 69% feel pressure to project happiness.

  • Post-Holiday Sentiments: After the holiday season, 59% of respondents typically feel positive or refreshed, while 17% experience sadness or disappointment.

[object Object]
Preview
4.0
09-30TipRanks
Top Analysts Recommend 3 Best Stocks to Purchase Now, 9/29/2025

  • Top Stock Picks: Analysts have identified three stocks—Lifestance Health Group, Glaukos, and Klaviyo, Inc.—as Strong Buys, each with significant upside potential based on recent ratings from top Wall Street analysts.

  • Lifestance Health Group: This Arizona-based mental health service provider has a 12-month price target suggesting a 64.84% upside, with all four top analysts recommending a Buy.

  • Glaukos: A medical technology company focused on eye treatments, Glaukos has a potential growth of 60.13% according to analysts, with four out of five top analysts giving it a Buy rating.

  • Klaviyo, Inc.: This Boston-based tech firm has a 12-month price target indicating a 46.83% growth potential, with all nine top analysts recently rating it as a Buy.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is LifeStance Health Group Inc (LFST) stock price today?

The current price of LFST is 6.46 USD — it has increased 0.94 % in the last trading day.

arrow icon

What is LifeStance Health Group Inc (LFST)'s business?

LifeStance Health Group, Inc. is a reimagining mental health company. The Company is focused on providing virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Its patient-focused platform combines differentiated clinical capabilities with a personalized, digitally powered patient experience designed to transform patient access and treatment. Its clinicians offer patients a comprehensive, multidisciplinary suite of mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders and post-traumatic stress disorder. It employs approximately 7,400 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers.

arrow icon

What is the price predicton of LFST Stock?

Wall Street analysts forecast LFST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFST is 9.00 USD with a low forecast of 8.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is LifeStance Health Group Inc (LFST)'s revenue for the last quarter?

LifeStance Health Group Inc revenue for the last quarter amounts to 363.81M USD, increased 16.34 % YoY.

arrow icon

What is LifeStance Health Group Inc (LFST)'s earnings per share (EPS) for the last quarter?

LifeStance Health Group Inc. EPS for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for LifeStance Health Group Inc (LFST)'s fundamentals?

The market is revising Upward the revenue expectations for LifeStance Health Group, Inc. (LFST) for FY2025, with the revenue forecasts being adjusted by 0.37% over the past three months. During the same period, the stock price has changed by 20.30%.
arrow icon

How many employees does LifeStance Health Group Inc (LFST). have?

LifeStance Health Group Inc (LFST) has 10218 emplpoyees as of December 05 2025.

arrow icon

What is LifeStance Health Group Inc (LFST) market cap?

Today LFST has the market capitalization of 2.51B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free